1 June 2022 - NICE has published evidence based recommendations on the use of filgotinib maleate (Jyseleca) for the treatment of adults with moderate to severe active ulcerative colitis.

Filgotinib maleate is recommended as an option for the treatment of adults with  moderate to severe active ulcerative colitis:

• When conventional or biological treatment cannot be tolerated, or
• If the disease has not responded well enough or has stopped responding to these treatments, and
• If Galapagos provides filgotinib according to the commercial arrangement.

Read NICE technology appraisal guidance